Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-cash Items: 2023-2025

Historic Non-cash Items for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $190.7 million.

  • CG Oncology's Non-cash Items rose 21.34% to $190.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.7 million, marking a year-over-year increase of 21.34%. This contributed to the annual value of $108.2 million for FY2024, which is 168.44% up from last year.
  • CG Oncology's Non-cash Items amounted to $190.7 million in Q3 2025, which was up 78.66% from $106.8 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Non-cash Items peaked at $231.2 million during Q1 2024, and registered a low of $40.3 million during Q4 2023.
  • Moreover, its 3-year median value for Non-cash Items was $130.6 million (2024), whereas its average is $134.3 million.
  • As far as peak fluctuations go, CG Oncology's Non-cash Items skyrocketed by 168.44% in 2024, and later slumped by 62.23% in 2025.
  • Quarterly analysis of 3 years shows CG Oncology's Non-cash Items stood at $40.3 million in 2023, then skyrocketed by 168.44% to $108.2 million in 2024, then grew by 21.34% to $190.7 million in 2025.
  • Its last three reported values are $190.7 million in Q3 2025, $106.8 million for Q2 2025, and $87.3 million during Q1 2025.